Rich Heyman joined Kalypsys Inc. as Senior Vice President of Drug Discovery in September 2006. He was formerly Senior Vice President of Metabolic Diseases and site head at the San Diego research site of Exelixis Inc. In 1999, he co-founded X-Ceptor Therapeutics, a drug discovery company that focused on the identification of new therapeutic agents targeting nuclear receptors for the treatment of metabolic diseases. He was Chief Scientific Officer and Sr. Vice President of Research at X-Ceptor prior to its acquisition by Exelixis in 2004. Prior to joining X-Ceptor, Dr. Heyman held the position of Vice President of Nuclear Receptor Discovery at Ligand Pharmaceuticals and was responsible for multiple drug discovery programs including the successful discovery and development of Panretin� and Targretin� retinoids approved for the treatment of cancer. Dr. Heyman has more than a dozen issued patents and co-authored over 100 scientific publications. He received his B.S. in Chemistry from the University of Connecticut, a Ph.D. in Pharmacology from the University of Minnesota.